The VEGF level in the vitreous fluid has been shown to be highly elevated in ROP patients [15,16], suggesting the potential of intravitreal injections of bevacizumab (IVB) for the treatment of ROP. This evidence concerns the gene VEGFA and retinopathy of prematurity.